Pharmafile Logo
Pharmafocus logo
Advanced Search

cardiovascular disease

Showing 15 posts of 20 posts found.

Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease

August 8, 2023
Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical

On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …

News
lilly_entrance_web

Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

February 24, 2020
Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …

News
novo_nordisk_flag

Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …

News
astrazeneca-sign

AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure

August 20, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …

News

Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease

August 1, 2019
Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …

News
diabetes-777001_960_720

Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …

News
amgen_flag

China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk

January 25, 2019
Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …

News
amgen_hq

Europe expands approved indication of Amgen’s Repatha in cardiovascular disease

May 17, 2018
Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …

News
finland_flag

Pfizer taps real world evidence for CVD in new partnership

February 14, 2018
Research and Development BC Platforms, Pfizer, biotech, cardiovascular disease, drugs, pharma, pharmaceutical

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …

News
heart-2338154_960_720

12% of the UK have hearts ten years older than they are, Public Health England finds

September 4, 2017
Research and Development, Sales and Marketing British Heart Foundation, Public Health England, cardiovascular disease, heart attack, heart health, stroke

New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are …

News
heart-2338154_960_720

Where will the next cardiovascular breakthrough come from?

August 17, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing British Heart Foundation, cardiovascular disease, heart, heart disease, pharma, pharmaceutical

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment …

Feature
choles

Battling misinformation on the world’s biggest killer

August 14, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cardiovascular disease, cholesterol, healthcare, heart disease, heart failure, medicine, pharma, pharmaceutical

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …

Feature
heart_image

Cardiovascular disease expected to place $1 trillion cost burden on US

February 20, 2017
Medical Communications, Sales and Marketing cardiovascular disease

A study conducted by RTI International, a non-profit research institute, has warned that the US could have to balance over …

News
pancreatic_cancer_research

Heart disease drug development is falling

August 30, 2016
Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development

The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …

News

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023